Novelion Therapeutics appoints Dr Mark Corrigan as Executive Chairman alongside Jeff Hackman as interim CEO

– CANADA, Vancouver – Novelion Therapeutics Inc. (NASDAQ / TSX:NVLN) today announced that Mark Corrigan, M.D. has been appointed as Executive Chair of the Board of Directors. As Executive Chair, Dr. Corrigan will serve in a supervisory role to the Company’s management team and will continue to perform the traditional duties of Board Chair.

In connection with Dr. Corrigan’s appointment, the Office of the CEO, which was comprised of Dr. Corrigan, Chief Operating Officer Jeff Hackman and former Chair Jason Aryeh, will be disbanded. As interim CEO, Mr. Hackman will lead the company’s operations, reporting into the Board.

“With two on-market rare disease therapies and an exciting metreleptin development plan anticipated to kick off this year, I believe Novelion has considerable future potential,” said Dr. Corrigan. “Much planning has been done to set Novelion on a growth trajectory, and I am pleased to have the opportunity to lead this capable management team and Board as we provide these needed therapies to our patients. On behalf of the Company, I would like to thank Jason for his many contributions and leadership role in establishing Novelion.”

About Novelion Therapeutics

Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a rare disease product portfolio through its subsidiary, Aegerion Pharmaceuticals, Inc. The Company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.

For more information : http://www.novelion.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>